<DOC>
	<DOCNO>NCT00925301</DOCNO>
	<brief_summary>The purpose study compare effect AT1001 ( migalastat hydrochloride ) versus placebo kidney GL-3 .</brief_summary>
	<brief_title>Study Effects Oral AT1001 ( Migalastat Hydrochloride ) Patients With Fabry Disease</brief_title>
	<detailed_description>This double-blind , randomize , placebo-controlled study conduct 60 patient approximately 40 site worldwide . The study consist two stage open-label treatment extension phase : Stage 1 include screening period 2 month follow 6-month treatment period involve 4 visit clinic . Patients randomize equal proportion receive either AT1001 placebo . After complete 6-month double-blind phase , patient enter Stage 2 study receive AT1001 open-label manner . Stage 2 treatment last 6 month involve 4 visit clinic . Subjects complete Stage 1 Stage 2 study schedule may offer opportunity participate open-label treatment extension phase AT1001 . The open-label treatment extension phase last 12 month involve 2 visit clinic . A follow-up visit undertaken 1 month follow completion discontinuation open-label treatment extension . Subjects complete 12 month open-label treatment extension provide consent enter separate long term extension require complete follow-up visit . Study assessment include clinical laboratory test , 12-lead ECG , kidney biopsy , kidney function testing , echocardiography , patient report outcome .</detailed_description>
	<mesh_term>Fabry Disease</mesh_term>
	<mesh_term>1-Deoxynojirimycin</mesh_term>
	<criteria>1 . Male female age 16 74 diagnosed Fabry disease 2 . Confirmed GLA mutation show responsive AT1001 vitro 3 . Subject never treat ERT receive ERT 6 consecutive month longer screen visit study 4 . Urine GL3 great equal four time upper limit normal Screening 5 . Subjects take angiotensin convert enzyme inhibitor ( ACEIs ) angiotensin receptor blocker ( ARBs ) must stable dose minimum 4 week baseline visit 6 . Women become pregnant men agree sexually abstinent use medically accept method birth control study 30 day study completion 7 . Subject willing able provide write informed consent , assent applicable 1 . Subject undergone schedule undergo kidney transplantation , currently dialysis 2. eGFR &lt; 30 mL/min/1.73m2 ( CKD Stage 4 5 ) base MDRD equation 3 . QTc ≥ 450 msec male ≥ 470 msec female Screening NOTE : Protocol Amendment 2.1 eliminates Exclusion Criterion # 3 . 4 . Pregnant breastfeed 5 . History allergy sensitivity study medication ( include excipients ) iminosugars ( e.g. , miglustat , miglitol ) 6 . Subject treat treated investigational drug within 30 day study start 7 . Subject currently treat ever treat AT1001 8 . Any intercurrent condition concomitant medication use consider absolute contraindication kidney biopsy may preclude accurate interpretation study data 9 . Otherwise unsuitable study , opinion Investigator</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>AmicusTherapeutics</keyword>
	<keyword>AT1001</keyword>
	<keyword>Migalastat</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Substrate</keyword>
</DOC>